Genzyme/Bayer Get FDA Approval For Campath As First-Line Treatment In Lymphocytic Leukemia
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer, who markets the mAb, does not plan any expansion of its 90-strong U.S. sales force in light of the label extension, firm tells “The Pink Sheet” DAILY.
You may also be interested in...
Genzyme Initiates Campath Phase III Study In Multiple Sclerosis
Firm and partner Bayer are on track to file alemtuzumab for relapsing-remitting MS in 2011, with a launch slated for 2012.
Genzyme Initiates Campath Phase III Study In Multiple Sclerosis
Firm and partner Bayer are on track to file alemtuzumab for relapsing-remitting MS in 2011, with a launch slated for 2012.
Cephalon Files Treanda For Chronic Lymphocytic Leukemia
Submission represents a milestone for Cephalon’s oncology program, firm says.